



Clover to Participate in Credit Suisse Asia Healthcare Corporate Day

June 7, 2022

SHANGHAI, China, June 07, 2022 (GLOBE NEWSWIRE) -- [Clover Biopharmaceuticals, Ltd.](#) (Clover; HKEX: 02197), a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, today announced its participation in Credit Suisse's Asia Healthcare Corporate Day, June 14-16, 2022.

Details of the conference and management participation are as follows:

Credit Suisse Asia Healthcare Corporate Day 2022

One-on-one and small group meetings: June 14 – 16, 2022

Participants: Management team and IR

For more information, please contact your Credit Suisse representative.

About Clover Biopharmaceuticals

Clover Biopharmaceuticals is a global clinical-stage biotechnology company committed to developing novel vaccines and biologic therapeutic candidates. The Trimer-Tag™ technology platform is a product development platform for the creation of novel vaccines and biologic therapies. Clover leveraged the Trimer-Tag™ technology platform to become a COVID-19 vaccine developer and created SCB-2019 (CpG 1018/Alum) to address the COVID-19 pandemic caused by SARS-CoV-2.

For more information, please visit Clover's website: www.cloverbiopharma.com and follow the company on [LinkedIn](#).

Clover Biopharmaceuticals:

Cindy Min

SVP, Public Affairs

media@cloverbiopharma.com

Naomi Eichenbaum

VP, Investor Relations

investors@cloverbiopharma.com